NASDAQ · Biotechnology

Ascendis Pharma A/S (ASND) Stock

$243.45 -0.19% NASDAQ: ASND Healthcare

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD).

Valuation

MetricValue
Price$243.45
Market Cap$15.12B
P/E Ratio25.59
P/B Ratio24.58
P/S Ratio13.77
EPS (TTM)$10.37
52-Week High$281.07
52-Week Low$160.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE332.65%
ROA-0.60%
ROCE80.37%
Gross Margin88.17%
Operating Margin-0.80%
Net Margin58.40%
Debt/Equity1.84
Current Ratio1.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$8.0M$51.0M$267.0M$364.0M$692.0M
Operating Profit$-452.0M$-562.0M$-456.0M$-279.0M$-131.0M
Net Profit$-384.0M$-583.0M$-481.0M$-378.0M$-219.0M
EPS$-7.00$-10.40$-8.55$-6.53$-3.62
Op Margin-5808.6%-1097.8%-170.8%-76.7%-18.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$1.1B$826.0M$1.2B$1.3B
Total Liabilities$201.0M$826.0M$971.0M$1.3B$1.5B
Cash$446.0M$445.0M$392.0M$560.0M$616.0M
Borrowings$210.0M$618.0M$743.0M$857.0M$871.0M

Latest News

FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo Zacks · Jul 14, 2026 Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia Simply Wall St. · Jul 12, 2026 Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% Simply Wall St. · Jul 12, 2026 Why Crinetics Stock Soared 99% This Week 24/7 Wall St. · Jul 9, 2026 Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-418.0M$-496.0M$-467.0M$-306.0M$52.0M
Investing Cash Flow$-135.0M$47.0M$284.0M$5.0M$-16.0M
Financing Cash Flow$-10.0M$-100.0M$8.0M$11.0M$-28.0M
Net Cash Flow$-138.0M$-1.0M$-53.0M$167.0M$123.0M
Free Cash Flow$-442.0M$-510.0M$-470.0M$-308.0M$44.0M

Valuation & Return Ratios

MetricValue
PEG Ratio60.83
EV / EBITDA-1356.41
FCF Yield0.35%
Quick Ratio0.72
Interest Coverage-1.70
Return 1Y51.89%
Return 3Y185.94%
Return 5Y117.47%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BBIOBridgeBio Pharma, Inc. $85.33 +1.56% -22.41 $16.71B 0.00%
BMRN $60.00 -0.04% 41.31 $11.60B 0.00%
EXELExelixis, Inc. $55.96 +0.27% 16.38 $14.07B 0.00%
GHGuardant Health, Inc. $145.13 -1.49% -43.46 $19.24B 0.00%
IONS $54.37 -2.84% -41.80 $8.99B 0.00%

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Ascendis Pharma A/S is led by CEO Jan Moller Mikkelsen, employs 1,017 people, headquartered in Hellerup, DK, publicly traded since 2015.

Ascendis Pharma A/S (ASND) stock trades at $243.45 with a market capitalization of $15.12B. The stock is valued at a price-to-earnings (P/E) ratio of 25.59, price-to-book of 24.58, price-to-sales of 13.77. Over the past 52 weeks the stock has ranged between $160.86 and $281.07, and currently trades 13.4% below its 52-week high.

On profitability, Ascendis Pharma A/S generates a return on equity (ROE) of 332.65% — well above the market average, a sign of a high-quality business, return on capital employed of 80.37%, an operating margin of -0.80%, a net profit margin of 58.40%.

In its most recent fiscal year, Ascendis Pharma A/S reported annual revenue of $692.0M, net profit of $-219.0M, revenue has compounded at 150.6% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 1.84, a current ratio of 1.04, total assets of $1.3B, $616.0M in cash and equivalents.

ASND has an average daily trading volume of 686,456 shares, a beta of 0.39 (less volatile than the overall market).

Official website: ascendispharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides